| Politician | Action | Description | Traded |
|---|---|---|---|
| Buy | Cassava Sciences, Inc. | Dec 12, 2022 | |
| Sell | Cassava Sciences, Inc. | Nov 8, 2022 | |
| Buy | Cassava Sciences, Inc. | Oct 12, 2022 | |
| Sell | Cassava Sciences, Inc. | Jul 18, 2022 | |
| Buy | Cassava Sciences, Inc. | Jun 21, 2022 |
This page tracks congressional stock trading activity in Cassava Sciences, Inc. (SAVA) in the Healthcare sector. Disclosed Capitol has indexed 5 disclosed congressional trades involving SAVA. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of January 2023 — Disclosed Capitol has tracked 5 disclosed congressional trades in Cassava Sciences, Inc. (SAVA) — 2 sells with no recorded buys — led by Christopher L. Jacobs (R).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Dec 12, 2022 | Christopher L. Jacobs | R | Buy | $1,001 - $15,000 |
| Nov 8, 2022 | Christopher L. Jacobs | R | Sale | $1,001 - $15,000 |
| Oct 12, 2022 | Christopher L. Jacobs | R | Buy | $1,001 - $15,000 |
| Jul 18, 2022 | Christopher L. Jacobs | R | Sale | $1,001 - $15,000 |
| Jun 21, 2022 | Christopher L. Jacobs | R | Buy | $15,001 - $50,000 |
Across the 5 disclosed congressional trades in Cassava Sciences, Inc. (SAVA), members of Congress have reported 0 buys and 2 sells. The average 30-day alpha vs. the S&P 500 is -14.82%.
For fiscal year 2025, Cassava Sciences, Inc. reported net income of -$97.2M, per SEC filings.
Most recent reported quarter: Q1 FY2026 — revenue —, net income -$10.3M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.